Invivo Therapeutics Holdings Corp (NASDAQ:NVIV)’s stock price fell 11.1% on Tuesday . The company traded as low as $0.23 and last traded at $0.24, 873,600 shares were traded during trading. An increase of 1,349% from the average session volume of 60,302 shares. The stock had previously closed at $0.27.
The company has a quick ratio of 4.01, a current ratio of 4.01 and a debt-to-equity ratio of 0.14. The company has a market cap of $4.11 million, a PE ratio of -0.11 and a beta of 1.35. The stock’s 50 day simple moving average is $0.46 and its two-hundred day simple moving average is $0.70.
Invivo Therapeutics (NASDAQ:NVIV) last posted its quarterly earnings results on Friday, November 8th. The biotechnology company reported ($0.29) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.33) by $0.04. Analysts forecast that Invivo Therapeutics Holdings Corp will post -1.21 EPS for the current year.
Invivo Therapeutics Company Profile (NASDAQ:NVIV)
InVivo Therapeutics Holdings Corp., a research and clinical-stage biomaterials and biotechnology company, engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries. It is developing Neuro-Spinal Scaffold implant, an investigational bioresorbable polymer scaffold for implantation at the site of injury within a spinal cord.
Recommended Story: What is a Real Estate Investment Trust (REIT)?
Receive News & Ratings for Invivo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Invivo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.